ELSEVIER
SAUNDERS

Prim Care Clin Office Pract
33 (2006) 965–972

PRIMARY CARE:
CLINICS IN
OFFICE PRACTICE

Index

Note: Page numbers of article titles are in **boldface** type.

A

Absolute risk and absolute risk reduction, definition of, 820

Abstracts, information from, 833–834

Acupuncture
for CAD, 877
for depression, 936

S-Adenosyl-L-methionine (SAMe), for depression, 933–934

Adolescents, depression in, 929

Adult Treatment Panel III guidelines, for hyperlipidemia, 903–910

Agency for Health Care Research and Quality, depression guidelines of, 934

Alcohol intake, CAD and, 876

Aldosteronism, hypertension in, 891

Alendronate, for osteoporosis, 948

Alternative therapies
for CAD, 876–877
for depression, 936
for hyperlipidemia, 917–918
for menopausal symptoms, 959–960

American College of Cardiology, coronary artery screening guidelines of, 864

American College of Obstetricians and Gynecologists, hormone replacement therapy guidelines of, 956

American College of Physicians, journal club, 818

American Diabetes Association, hypertension treatment guidelines of, 895

American Family Physician, web site, 818

American Heart Association, coronary artery screening guidelines of, 864

Amlodipine, for hypertension, 893

Angina, treatment of. *See* Coronary artery disease, treatment of.

Angiography, coronary, for screening, 867–868

Angioplasty, coronary, 873–874

Angiotensin-converting enzyme inhibitors
for CAD, 872–873
for hypertension, 893–895

Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm, 908

Anticoagulants, for coronary artery disease, 870–871

Anticonvulsants, for depression, 928

Antidepressants
after myocardial infarction, 930–931
after stroke, 930–931
duration of therapy with, 928
first-line, 926–927
for menopausal symptoms, 961
for pediatric patients, 929
in collaborative programs, 935–936
in pregnancy, 929–930
new versus old, 925
nonresponse to, 927–928
side effects of, 926

Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, 893

Antiplatelet therapy, for coronary artery disease, 870–871

Anxiety, depression with, 928

Aortic coarctation, hypertension in, 891

ASCOTT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm), 908

Aspirin, for coronary artery disease, 870–871

Atorvastatin, for hyperlipidemia, 908

0095-4543/06/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/S0095-4543(06)00102-3

B

Bandolier web site, 818

Benzodiazepines, for depression, 928

Beta blockers
for CAD, 872, 894–895
for hypertension, 893–895

Beta-Blocker Heart Attack Trial, 894–895

Bias, definition of, 820

Bile-acid sequestrants, for hyperlipidemia, 913

Biochemical markers, for CAD, 868

Bisoprolol, for hypertension, 894

Bisphosphonates, for osteoporosis, 948

Blind studies, 849

Blinding, definition of, 820

Blood Pressure Lowering Treatment Trialist's Collaboration Trial, 893

Bone loss. *See* Osteoporosis.

Bone mineral density measurement, in osteoporosis, 947–948

Botanicals, for menopausal symptoms, 959–960

Breast cancer, in hormone replacement therapy, 953–956

Bright light therapy, for depression, 934–935

Bupropion, for depression, 925–927, 929–930

C

CAD. *See* Coronary artery disease.

Calcitonin, for osteoporosis, 949

Calcium, for osteoporosis, 944

Calcium channel blockers, for CAD, 873

Cancer, breast, in hormone replacement therapy, 953–956

CAPRICORN trial, 894–895

Captopril, for hypertension, 893–894

Cardiac Arrhythmia Suppression Trial, 814

Cardiac rehabilitation, 876

Cardiac stress imaging, in CAD, 866–867

Carvedilol, for hypertension, 893–894

Case reports, 817, 821

Case-control studies, 822

Categorical (nominal) data, 850–851

Causation, information on, evaluation of, 859

Chest radiography, in CAD, 879

Chinese medicine
for CAD, 877
for depression, 936

Chlorthalidone, for hypertension, 893

Cholesterol, elevated. *See* Hyperlipidemia.

Citalopram, for depression, 929

Clinical Evidence web site, 818

Clinical practice guidelines, 825–826

Clinical significance, versus statistical significance, 850

Clonazepam, for depression, 928

Clonidine, for menopausal symptoms, 960–961

Clopidogrel, for coronary artery disease, 870–871

Cochrane Collaboration, on antidepressants, 926

Cochrane Database of Systematic Reviews, 818, 835

Cochrane Library, 835

Cognitive behavioral treatment, for depression, 931–932

Cohort studies, 822–823

Collaborative therapy, for depression, 935–936

Complementary therapies. *See* Alternative therapies.

Computed tomography, electron beam, in CAD, 867

Concealment of allocation, definition of, 820

Confidence intervals, 820, 850, 852

Congestive heart failure, hypertension in, 893–894

Continuous (interval) data, 850–851

Control groups, 849

Coronary angiography, for screening, 867–868

Coronary angioplasty, 873–874

Coronary artery bypass graft surgery, for CAD, 873–874

Coronary artery disease, **863–885**
depression in, 930–931
epidemiology of, 863
hyperlipidemia and, 903–911
risk factors for, 864–865, 904–905
screening for
biochemical markers in, 868
cardiac stress imaging in, 866–867
decisions on, 864
electrocardiography in, 866
electron beam computed tomography in, 867
exercise treadmill testing in, 866
in diabetes mellitus, 868–869
in professions involving public safety, 869
invasive testing in, 867–868
methods for, 866–870
preoperative, 869–870
preparticipation, 869
probability considerations in, 864–865
treatment of, 870–879
alternative, 876–877
angiotensin-converting enzyme inhibitors in, 872–873
antihypertensives in, 872
antiplatelet therapy in, 870–871
beta blockers in, 872
calcium channel blockers in, 873
follow-up in, 879–880
lipid-lowering, 871–872
monitoring of, 877–879
nitrates in, 873
revascularization in, 873–874
risk factor modification in, 874–876
with hypertension, 894–895

Coronary Drug Project, 910

Cost-benefit analysis, 853

Counseling
for depression, 931–932
for type A behavior, in CAD, 875–876

C-reactive protein, in CAD screening, 868

Cross-sectional (prevalence) studies, 821

Cushing's syndrome, hypertension in, 891

D

DARE (Database of Abstracts of Reviews of Effects), 818, 835

DASH (Dietary Approaches to Stop Hypertension) Plan, 896

Database of Abstracts of Reviews of Effects (DARE), 818, 835

Decision analyses, 824–825

Dehydroepiandrosterone, for depression, 933–934

Dementia, in hormone replacement therapy, 954

Depression, **923–941**
causes of, 924
diagnostic criteria for, 924
epidemiology of, 923
genetic factors in, 924
screening for, 924–925
treatment of
alternative therapies in, 936
antidepressants for, 925–931
collaborative therapy in, 935–936
counseling in, 931–932
exercise in, 932–933
herbal remedies in, 933
hormonal supplements in, 933–934
in cardiovascular disease, 930–931
in pediatric patients, 929
in pregnancy, 929–930
light therapy in, 934–935
nonresponse to, 927–928

Diabetes mellitus
coronary artery disease screening in, 868–869
hyperlipidemia with, 912
hypertension with, 895

Diagnostic tests, information on, evaluation of, 858–859

Diamond-Forrester method, for estimating coronary artery disease risk, 864–865

Diet, for hyperlipidemia, 917–918

Dietary Approaches to Stop Hypertension Diet (DASH) Plan, 896

Diuretics, for hypertension, 893

Dobutamine stress echocardiography, in CAD, 867

Dong quai, for menopausal symptoms, 960

Dr. Alper's Useful Links, 818

Dual-energy x-ray absorptiometry scanning, in osteoporosis, 947–948

Duke University, web-based courses from, 812

DynaMed web site, 818

Dyslipidemia. *See* Hyperlipidemia.

E

Echocardiography, in CAD, 867, 879

Effect of Captopril on Mortality and Morbidity In Patients with Left Ventricular Dysfunction After Myocardial Infarction trial, 894

Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure Trial, 894

Elderly persons, hyperlipidemia treatment in, 906

Electrocardiography, in CAD screening, 866

Electron beam computed tomography, in CAD, 867

Enalapril, for hypertension, 893–894

Epocrates Hypertension Quick Reference for PDAs, 896

Errors, in statistical analysis, 850

Estrogens, replacement of. *See* Hormone replacement therapy.

European Trial on Reduction of Cardiac Events with Perindopril in Patients with Coronary Artery disease, 894–895

Evening primrose, for menopausal symptoms, 959–960

Evidence-based medicine, **811–829**
  advantages of, 813
  coronary artery disease screening, **863–885**
  definition of, 813
  depression, **923–941**
  focus of, 814–815
  hierarchy of evidence in, 822
  hormone replacement therapy. *See* Hormone replacement therapy.
  hyperlipidemia, 871–872, **903–921**
  hypertension therapy, **887–901**
  information resources for. *See* Information resources.
  journals including articles on, 826–827
  osteoporosis, **943–951**
  steps of, 815–827
    assessing evidence, 817, 821–825
    developing answerable question, 815–816
    evaluating performance of evidence, 826–827
    implementing useful evidence, 825–826
    searching for evidence, 816–819
  terminology used in, 820–821
  web-based courses on, 812–813

Exercise
  for CAD, 875
  for depression, 932–933
  for osteoporosis, 944

Exercise treadmill testing, in CAD, 866, 879

Ezetimibe, for hyperlipidemia, 913

F

Family Practitioners Inquiries Network (FPIN), 819

Fiber, dietary, for hyperlipidemia, 917–918

Fibrates, for hyperlipidemia, 911, 913

FIRSTConsult web site, 819

Fish oils, for hyperlipidemia, 917–918

Fluoxetine, for depression, 925, 928–931

FPIN (Family Practitioners Inquiries Network), 819

Fractures, in osteoporosis, 943

Framingham Risk Score, for coronary artery disease, 865

G

Garlic
  for CAD, 877
  for hyperlipidemia, 917–918

Gemfibrozil, for hyperlipidemia, 909–910

H

Heart failure, hypertension in, 893–894

Heart Outcomes Prevention Evaluation, 894–895

Heart Protection Study, 907

Hepatotoxicity, in statin therapy, 915

Herbal remedies
  for CAD, 877
  for depression, 933

Hormone replacement therapy, 814–815, **953–963**
alternatives to, 959–960
contraindications to, 960
estrogen dose equivalents for, 958
evidence for, 953–956
for depression, 933–934
for osteoporosis, 949
guidelines for, 956–957
low-dose, 957
nonoral, 957–958
off-label, 960–961
testosterone in, 959

Hypericum, for depression, 933

Hyperlipidemia, **903–921**
epidemiology of, 903
laboratory tests in, 916
treatment of
alternative therapies in, 917–918
combination therapies in, 913–914
goals of, 906–909
in coronary artery disease, 871–872
outcomes of, 911–912
patient selection for, 904–906
side effects of, 914–915
with hypertriglyceridemia, 909–910
with low high-density lipoprotein, 909

Hyperparathyroidism, hypertension in, 891

Hypertension, **887–901**
definition of, 887
epidemiology of, 887
evaluation of, 890–891
genetics of, 888
guidelines on, 889–890
pathophysiology of, 888
prognosis for, 888–889
secondary, 891
treatment of
essential, 892–893
in CAD, 872
lifestyle modifications in, 891–892
quick reference for, 896
with coronary artery disease, 894–895
with diabetes mellitus, 895
with heart failure, 893–894

Hypertriglyceridemia, treatment of, 871–872, 909–910

Hypothyroidism, hypertension in, 891

I

Imipramine, for depression, 929

InfoPOEMs–The Clinical Awareness System, 819

InfoRetriever, 835

Information resources, **831–837**
barriers to finding, 832
critical evaluation of, **839–862**
on reading skills, 853–857
steps in, 841–853
determining intent, 844
evaluating validity based on intent, 844–853, 857–860
initial validity and relevance screen, 841–843, 857
educational, 812–813, 834
for busy clinicians, 818–819
for critical reading skills, 853–857
for hypertension, 896–897
influenced by commercial interests, 842–843
journals, 826–827
needs for, 832
overwhelming volume of, 839
primary articles, 840
relevance of, 832
secondary studies, 840
types of, 832–835
web-based courses, 812–813

Institute for Clinical Systems Improvement (ISCI), 819, 927

Integrative studies, 823–825

Internet, evidence-based medicine courses on, 812–813

Introduction to Information Mastery web site, 812

ISCI (Institute for Clinical Systems Improvement), 819, 927

J

Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Seventh Report of, 889–890

Journal of Family Practice, 819

Journals
critical evaluation of, 839–862
peer-reviewed, 841–842

K

Kidney dysfunction, hypertension in, 891

Knowledge. *See* Information resources.

L

Library of Health Sciences, Peoria, Illinois, web-based courses from, 812

Lifestyle modifications, for hypertension, 891–892

Light therapy, for depression, 934–935

Likelihood ratio, definition of, 820

Lipid-lowering treatment. *See* Hyperlipidemia, treatment of.

Lipoproteins, elevated. *See* Hyperlipidemia.

Lisinopril, for hypertension, 893

Lithium, for depression, 927–928

Liver toxicity, in statin therapy, 915

M

McMaster University, research article screening guide, 841–853

Maprotiline, for depression, 929

Medical Subject Headings, 833

Mediterranean diet, for hyperlipidemia, 917–918

Medline, 832–833

Menopause symptoms, hormone replacement therapy for. *See* Hormone replacement therapy.

MESH (Medical Subject Headings), 833

Meta-analysis, 824

Metoprolol, for hypertension, 894

Million Women Study, hormone replacement therapy guidelines of, 955

Mirtazapine, for depression, 925, 927

Myocardial infarction, depression after, 930–931

Myocardial perfusion imaging, in CAD, 866–867

Myopathy, in statin therapy, 914–915

N

National Cholesterol Education Program Adult Treatment Panel III guidelines, for hyperlipidemia, 903–910

National Library of Medicine, Medline, 832–833

National Osteoporosis Foundation, 943

Natriuretic peptide, in CAD screening, 868

Nefazodone, for depression, 925–926

Negative predictive value, definition of, 820

Negative trials, 852

Neonates, maternal antidepressant effects on, 930

Netherlands Trial, hormone replacement therapy guidelines of, 955

Netting the Evidence web site, 813

Neurotransmitter hypothesis, for depression, 924

Niacin, for hyperlipidemia, 909–911, 913

Nitrates, for CAD, 873

N-of-1 randomized trials, 822–823

North American Menopause Society, hormone replacement therapy guidelines of, 956–957

North Carolina Evidence-Based Medicine Education Center of Excellence, web-based courses from, 812

Nortriptyline, for depression, 929

Norwegian Multicenter Study of Timolol after Myocardial Infarction trial, 894–895

Number needed to treat, definition of, 820

Nutrition, for hyperlipidemia, 917–918

O

Obesity, treatment of, for CAD, 875

Occupational screening, for CAD, 869

Omega-3 fatty acids, for hyperlipidemia, 872, 911, 917–918

Ordinal data, 850–851

Osteoporosis, **943–951**
- bone mineral density scan in, 947–948
- definition of, 943
- epidemiology of, **943**
- prevention of, 944–945
- risk factors for, 945–947
- screening for, 945–948
- statin use and, 912
- treatment of, 948–950
- ultrasonography in, 948

Otitis media, 815

Outcomes
as focus, 814
factors affecting, 852–853

Oxford-Centre, web-based courses from, 813

P

P value, in statistics, 850

Parathyroid hormone, for osteoporosis, 950

Paroxetine, for depression, 925, 929–930

Pediatric patients, depression in, 929

Perindopril
for CAD, 872–873
for hypertension, 895

Pheochromocytoma, hypertension in, 891

Phototherapy, for depression, 934–935

Phytoestrogens, for menopausal symptoms, 960

PICO model, 816

Placebos, 849

POEMS (patient-oriented evidence that matters), 832

Positive predictive value, definition of, 821

Posttest probability, definition of, 821

Power analysis, 852

Pravastatin, for hyperlipidemia, 908

Predictive value, definition of, 820–821

Pregnancy, depression in, 929–930

Prehypertension, 889–890

Preoperative evaluation, for CAD, 869–870

Preparticipation testing, for CAD, 869

Pretest probability, definition of, 821

Prevention of Events with Angiotensin-Converting Enzyme Inhibition Trial, 894–895

Primary studies, 817

Prognosis, information on, evaluation of, 860

Prospective studies, 847–849

PROVE IT study, 908

Psychotherapy, for depression, 931–932

PubMed searches, 833

Q

Question, in evidence-based medicine model, 815–816

R

Raloxifene, for osteoporosis, 949–950

Ramipril, for CAD, 872–873

Randomized controlled trials, 822, 824, 845–849

Red yeast rice, for hyperlipidemia, 917–918

Rehabilitation, cardiac, 876

Relevance, of evidence, 817, 821–825

Renovascular hypertension, 891

Resources, information. *See* Information resources.

Revascularization, for CAD, 873–874

Review articles, 823–825, 834–835

Risedronate, for osteoporosis, 948

S

St. John's wort, for depression, 933

SAMe (S-adenosyl-L-methionine), for depression, 933–934

Scandinavian Simvastatin Survival Study, 912

Screening
for coronary artery disease, **863–885**
for depression, 924–925

Selective serotonin reuptake inhibitors, for depression, 925–930

Sensitivity, definition of, 821

Sertraline, for depression, 925, 929–930, 932

Sexual dysfunction, due to antidepressants, 926

Shape Up America, 896–897

Sildenafil, for antidepressant-induced sexual dysfunction, 926

Simvastatin, for hyperlipidemia, 912–913

Sleep apnea, hypertension in, 891

Smoking cessation
for CAD, 874–875
for osteoporosis, 947

Soy products
for hyperlipidemia, 917–918
for menopausal symptoms, 960

Specificity, definition of, 821

Spinal cord stimulation, for CAD, 876–877

State University of New York Downstate Medical Center, web-based courses from, 812

Statins, for hyperlipidemia, 905–915
goals of, 906–909
in combination therapy, 913–914
indications for, 909–910
outcomes of, 911–912
side effects of, 914–915

Statistics, in study evaluation, 849–852

Stents, for CAD, 873–874

Strength of Recommendation Taxonomy, 825

Stress testing, in CAD, 866–867, 879

Stroke
depression after, 930–931
prevention of, lipid-lowering treatment in, 911–912

Suicidal ideation, due to antidepressants, 926

SUMSearch web site, 819

Survival of Myocardial Infarction Long-Term Evaluation Study, 894–895

Swedish Trial in Old Patients with Hypertension-2 Study, 893

Systematic reviews, 823–825

T

Teriparatide, for osteoporosis, 950

Testosterone, for libido enhancement, 959

Thiazides, for hypertension, 892–893

Thyroid hormone, for depression, 928

Ticlodipine, for coronary artery disease, 870–871

Trandolapril Cardiac Evaluation, 894–895

Tricyclic antidepressants, for depression, 925–927

Triglycerides, elevated, treatment of, 871–872, 909–910

Triiodothyronine, for depression, 928

U

Ultrasonography, in osteoporosis, 948

United States National Guideline Clearinghouse, 819

United States Preventive Services Task Force
coronary artery screening guidelines of, 864
depression screening guidelines of, 924–925
hormone replacement therapy guidelines of, 956
web site of, 819

University of North Carolina, web-based courses from, 812

University of Rochester, web-based courses from, 812

University of Virginia, web-based courses from, 813

UpToDate web site, 819

V

VA-HIT (Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial), 910

Validity
of evidence, 817, 821–825, 857–860
statistical study of, 849–852

Venlafaxine, for depression, 925–927, 929–930

Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial, 910

Vitamin D, for osteoporosis, 944–945

W

Warfarin, for coronary artery disease, 871

Weight loss, for CAD, 875

Women's Health Initiative, 814–815, 953–954